logo BDSP

Base documentaire


  1. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia : The optimal duration of therapy.

    Article - En anglais

    Study objective 

    To compare therapeutic outcome and perform a cost-benefit analysis of inpatients with community-acquired pneumonia (CAP) treated with a shortened course of IV antibiotic therapy.

    Design 

    A prospective, randomized, parallel group study with a follow-up period of 28 days.

    Setting 

    Bronx Veterans Affairs Medical Center (VAMC) and the Castle Point VAMC ; university-affiliated VAMC general medical wards from September 1993 to March 1995.

    Patients 

    Seventy-two male veterans and 1 female veteran with 75 episodes of CAP defined by a new infiltrate on chest radiograph and either history or physical findings consistent with pneumonia.

    Study population was 42% (31) black, 33% (24) white, and 25% (18) Hispanic.

    Interventions 

    Patients were randomized (1 : 1 : 1) to 1 of 3 treatment groups :

    • group 1 received 2 days of IV and 8 days of oral therapy ;

    • group 2 received 5 days of IV and 5 days of oral therapy ;

    • and group 3 received 10 days of IV therapy.

    Antibiotics consisted of cefuroxime, 750 mg every 8 h for the IV course, and cefuroxime axetil, 500 mg every 12 h for the oral therapy.

    Measurements and results 

    No differences were found in the clinical course, cure rates, or resolution of chest radiograph abnormalities among the three groups.

    A significant difference was found in the length of stay (LOS) among the three groups.

    The mean ± SD LOS was 6±3 days in group 1,8±2 days in group 2, and 11 ± 1 days in group 3. (...)

    Mots-clés Pascal : Pneumonie, Bactériose, Infection, Traitement, Chimiothérapie, Antibiotique, Voie intraveineuse, Optimisation, Temps traitement, Analyse coût, Résultat, Homme, Appareil respiratoire pathologie, Poumon pathologie, Economie santé

    Mots-clés Pascal anglais : Pneumonia, Bacteriosis, Infection, Treatment, Chemotherapy, Antibiotic, Intravenous administration, Optimization, Processing time, Cost analysis, Result, Human, Respiratory disease, Lung disease, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0483459

    Code Inist : 002B02S02. Création : 10/04/1997.